Alitretinoin
- Generic Name
- Alitretinoin
- Brand Names
- Panretin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 5300-03-8
- Unique Ingredient Identifier
- 1UA8E65KDZ
- Background
An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. I...
- Indication
外用可用于局部治疗艾滋病相关的卡波西肉瘤且未接受全身治疗的皮肤损伤。口服可用于局部外用强效糖皮质激素无效的慢性手部湿疹患者。
- Associated Conditions
- Chronic Eczema of the hand, Cutaneous lesions, Refractory Eczema of the hand, Severe Eczema of the hand
- Associated Therapies
- -
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 250
- Registration Number
- NCT00309621
- Locations
- 🇩🇪
Abt. Klinische Sozialmedizin, Heidelberg, Germany
Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 300
- Registration Number
- NCT00124436
- Locations
- 🇩🇪
Thomas Ruzicka, Düsseldorf, Germany
Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 1035
- Registration Number
- NCT00124475
- Locations
- 🇩🇪
Thomas Ruzicka, MD, Düsseldorf, Germany
A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Anderson Clinical Research
- Target Recruit Count
- 27
- Registration Number
- NCT00002188
A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma
Not Applicable
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Anderson Clinical Research
- Registration Number
- NCT00002439
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients
Phase 1
Completed
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00001504
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath